Beta-adrenergic receptor blocker propranolol triggers anti-tumor immunity and enhances irinotecan therapy in mice colorectal cancer

• Published in: European journal of pharmacology Vol. 949; p. 175718
• Main Authors: Lin, Yanting, Liu, Yiming, Gao, Zhenhua, Jing, Dongquan, Bi, Ran, Cui, Xinmeng, Cao, Qiuhua, Zhao, Qixiang, Gao, Rui, Su, Yali, Liu, Siliang, Zhao, Mingrui, Yang, Yong, Chen, Anqi, Dai, Beiying, Gao, Xinghua
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 15.06.2023
• Subjects: Adrenergic beta-Antagonists - pharmacology; Adrenergic beta-Antagonists - therapeutic use; Animals; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Colorectal Neoplasms - pathology; CRC; Drug repurposing; Irinotecan - pharmacology; Irinotecan - therapeutic use; Mice; Mice, Nude; Propranolol; Propranolol - pharmacology; Propranolol - therapeutic use; T-cell exhaustion; Drug repurposing; T-cell exhaustion; Propranolol; CRC

Colorectal cancer (CRC) stands as the second leading cause of cancer-related deaths worldwide with limited available medicines. While drug repurposing comes as a promising strategy for cancer treatment, we discovered that propranolol (Prop), a non-selective β1 and β2 adrenergic receptor blocker, sig...